ELOX vs. ONVO, COEP, BCDA, GENE, CHRO, CELZ, TTNP, SRNE, FRTX, and KRBP
Should you be buying Eloxx Pharmaceuticals stock or one of its competitors? The main competitors of Eloxx Pharmaceuticals include Organovo (ONVO), Coeptis Therapeutics (COEP), BioCardia (BCDA), Genetic Technologies (GENE), Chromocell Therapeutics (CHRO), Creative Medical Technology (CELZ), Titan Pharmaceuticals (TTNP), Sorrento Therapeutics (SRNE), Fresh Tracks Therapeutics (FRTX), and Kiromic BioPharma (KRBP). These companies are all part of the "biological products, except diagnostic" industry.
Organovo (NASDAQ:ONVO) and Eloxx Pharmaceuticals (NASDAQ:ELOX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, community ranking, dividends and earnings.
Organovo's return on equity of 0.00% beat Eloxx Pharmaceuticals' return on equity.
Organovo received 183 more outperform votes than Eloxx Pharmaceuticals when rated by MarketBeat users. Likewise, 50.13% of users gave Organovo an outperform vote while only 43.33% of users gave Eloxx Pharmaceuticals an outperform vote.
Organovo has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals has a beta of 2.71, suggesting that its stock price is 171% more volatile than the S&P 500.
8.2% of Organovo shares are held by institutional investors. Comparatively, 2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. 4.0% of Organovo shares are held by company insiders. Comparatively, 20.2% of Eloxx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Organovo has higher revenue and earnings than Eloxx Pharmaceuticals. Organovo is trading at a lower price-to-earnings ratio than Eloxx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Eloxx Pharmaceuticals has a consensus price target of $55.00, suggesting a potential upside of 6,370.59%. Given Organovo's higher possible upside, analysts plainly believe Eloxx Pharmaceuticals is more favorable than Organovo.
In the previous week, Organovo had 4 more articles in the media than Eloxx Pharmaceuticals. MarketBeat recorded 4 mentions for Organovo and 0 mentions for Eloxx Pharmaceuticals. Eloxx Pharmaceuticals' average media sentiment score of 0.97 beat Organovo's score of 0.00 indicating that Organovo is being referred to more favorably in the media.
Summary
Organovo beats Eloxx Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
Get Eloxx Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELOX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ELOX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eloxx Pharmaceuticals Competitors List
Related Companies and Tools
